* Alzamend Neuro Inc reported a quarterly adjusted loss of 44 cents per share for the quarter ended in October, higher than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of two analysts for the quarter was for a loss of 67 cents per share. Wall Street expected results to range from -75 cents to -60 cents per share.
* Reported revenue was zero; analysts expected zero.
* Alzamend Neuro Inc's reported EPS for the quarter was a loss of 44 cents.
* The company reported a quarterly loss of $2.91 million.
* Alzamend Neuro Inc shares had fallen by 70.5% this quarter and lost 87.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 12.5% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Alzamend Neuro Inc is $56.25 This summary was machine generated from LSEG data December 15 at 10:37 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Oct. 31 2023 -0.67 -0.44 Beat
Jul. 31 2023 -0.52 -0.60 Missed
Apr. 30 2023 -0.67 -0.45 Beat
Jan. 31 2023 -0.60 -0.90 Missed
Comments